You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

Authors

  • Jieqiong Liu Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Qiang Liu Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Ying Li Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Qian Li Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Fengxi Su Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Herui Yao Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Shicheng Su Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Quanren Wang Jiangsu Hengrui Medicine Co., Ltd, Jiangsu, China PubMed articlesGoogle scholar articles
  • Liang Jin Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Ying Wang Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Wan Yee Lau Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hongkong, China PubMed articlesGoogle scholar articles
  • Zefei Jiang Department of Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Erwei Song Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China Fountain-Valley Institue for Life Sciences, 4th Floor, Building D, Guangzhou Institue of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China PubMed articlesGoogle scholar articles

Citation

Liu J, Liu Q, Li Y, et al
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Journal for ImmunoTherapy of Cancer 2020;8:e000696. doi: 10.1136/jitc-2020-000696
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.